Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Common Equity (2023 - 2025)

Historic Common Equity for Connect Biopharma Holdings (CNTB) over the last 3 years, with Q3 2025 value amounting to $55.4 million.

  • Connect Biopharma Holdings' Common Equity changed N/A to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.4 million, marking a year-over-year change of. This contributed to the annual value of $92.2 million for FY2024, which is 919.34% down from last year.
  • According to the latest figures from Q3 2025, Connect Biopharma Holdings' Common Equity is $55.4 million.
  • In the past 5 years, Connect Biopharma Holdings' Common Equity registered a high of $110.5 million during Q2 2024, and its lowest value of $9000.0 during Q2 2023.
  • For the 3-year period, Connect Biopharma Holdings' Common Equity averaged around $73.4 million, with its median value being $82.9 million (2025).
  • Its Common Equity has fluctuated over the past 5 years, first soared by 122744444.44% in 2024, then plummeted by 3542.48% in 2025.
  • Connect Biopharma Holdings' Common Equity (Quarter) stood at $101.5 million in 2023, then fell by 9.19% to $92.2 million in 2024, then tumbled by 39.92% to $55.4 million in 2025.
  • Its Common Equity stands at $55.4 million for Q3 2025, versus $71.3 million for Q2 2025 and $82.9 million for Q1 2025.